Kymera Therapeutics

Kymera Therapeutics to Participate in Upcoming January and February Investor Conferences

WATERTOWN, Mass., Jan. 25, 2022 (GLOBE NEWSWIRE) — Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the Company will participate in the